Cargando…
Genetically proxied therapeutic prolyl-hydroxylase inhibition and cardiovascular risk
Prolyl hydroxylase (PHD) inhibitors are in clinical development for anaemia in chronic kidney disease. Epidemiological studies have reported conflicting results regarding safety of long-term therapeutic haemoglobin (Hgb) rises through PHD inhibition on risk of cardiovascular disease. Genetic variati...
Autores principales: | Harlow, Charli E, Patel, Vickas V, Waterworth, Dawn M, Wood, Andrew R, Beaumont, Robin N, Ruth, Katherine S, Tyrrell, Jessica, Oguro-Ando, Asami, Chu, Audrey Y, Frayling, Timothy M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851745/ https://www.ncbi.nlm.nih.gov/pubmed/36048866 http://dx.doi.org/10.1093/hmg/ddac215 |
Ejemplares similares
-
Identification and single-base gene-editing functional validation of a cis-EPO variant as a genetic predictor for EPO-increasing therapies
por: Harlow, Charli E., et al.
Publicado: (2022) -
The role of HIF prolyl hydroxylases in tumour growth
por: Jokilehto, Terhi, et al.
Publicado: (2010) -
Function and expression of prolyl hydroxylase 3 in cancers
por: Liu, Qiu-long, et al.
Publicado: (2013) -
Microbiota-derived butyrate is an endogenous HIF prolyl hydroxylase inhibitor
por: Wang, Ruth X., et al.
Publicado: (2021) -
Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state
por: Joharapurkar, Amit A., et al.
Publicado: (2022)